NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Immunome, Inc. (IMNM) Stock Analysis

Immunome, Inc. (IMNM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

IMNM

$18.00

+$0.08 (+0.45%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IMNM with… →

IMNM Key Statistics

As of Oct 21, 2026
Trading
Open
$17.99
Previous Close
$17.92
Day's Range
17.85–18.44
52-Week Range
14.64–30.06
Volume
1.55M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.56
Valuation
Market Cap
$2.12B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.52
Financials (FY)
Revenue (FY)
$6.94M−23.23%
Net Income (FY)
−$212.39M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
118.00M
1-Year Return
+7.53%
Dividend and dates
Earnings Date
November 5, 2026estimated
Avg Volume
1.24M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IMNM closed at $18.00, +7.53% over 1 year.

Immunome, Inc. (IMNM) has a market capitalization of $2.12B.

In fiscal 2025, IMNM reported revenue of $6.94M.

IMNM Stock Return by Calendar Year

Immunome, Inc. (IMNM) return since Oct 2020: what $10,000 became

1 year
$10,000 $10,753
+7.53%
5 years
$10,000 $9,923
−0.77%
Since Oct 2020
$10,000 $13,383
+33.83%

If you had invested $10,000 in Immunome, Inc. (IMNM) at the close on October 2, 2020, the earliest close on record here, it would have been worth $13,383 at the close on October 21, 2026: +33.83% in total, +4.93% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−16.20%
2025+102.26%
2024−0.75%
2023+384.16%
2022−82.95%
2021+33.88%
2020 (partial year)−28.03%

As of October 21, 2026.

IMNM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$6.94M−$212.39M−3,060.0%
2024$9.04M−$292.96M−3,240.4%
2023$14.02M−$106.81M−761.9%
2022$0.00−$36.90M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$6.94M—−$224.11M−$212.39M−3,060.0%
2024$9.04M—−$153.46M−$292.96M−3,240.4%
2023$14.02M—−$28.73M−$106.81M−761.9%
2022$0.00—−$36.90M−$36.90M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 15 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Immunome, Inc. (IMNM) carries a market capitalisation of $2.12B. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 247 employees.

Over the past 52 weeks the price has ranged from $14.64 to $30.06. The most recent close on file for IMNM is $18.00, dated October 21, 2026. That is +$0.08 (+0.45%) against the previous close. The latest close sits 22.95% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $6.94M. Against the prior fiscal year total of $9.04M, that is a change of −23.23%. The same year closed with a net loss of $212.39M. Trailing earnings per share are −2.52.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $6.94M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The trailing one-year total return is +7.53%. Measured over 5 years, that is −0.15% a year compounded. Beta against the wider market is reported at 2.56. Annualized volatility over the trailing 6 years is 97.13%.

Growth & Income

No dividend is on file for IMNM.

2026 is still running; the total return is −16.20% year to date. The strongest complete calendar year on file is 2023 at +384.16%; the weakest is 2022 at −82.95%. Of the 5 complete calendar years on file, 3 finished higher.

Peer Comparison

Immunome, Inc. (IMNM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Immunome, Inc. IMNM $2.12B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Immunome, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Immunome, Inc.

Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Visit website →